About Immunogenx
Immunogenx is a company based in Durham (United States) founded in 2013. The company has 6 employees as of December 31, 2022. Immunogenx has completed 1 acquisition, including Alvine Pharma. Immunogenx offers products and services including Therapeutic Solution. Immunogenx operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Durham, United States
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunogenx, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.2 M (USD), Grant
Sep 08, 2020
- Investors
-
Employee Count
6
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immunogenx
Immunogenx offers a comprehensive portfolio of products and services, including Therapeutic Solution.
Develops therapies to address gluten-free diet challenges for celiac disease patients.
People of Immunogenx
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Immunogenx
Investors in Immunogenx
Immunogenx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Immunogenx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunogenx
Immunogenx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alvine Pharma.
Investment portfolio details for Immunogenx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing therapeutics for autoimmune and inflammatory diseases.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Immunogenx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Immunogenx
Detailed financials for Immunogenx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunogenx Comparisons
Peer comparison for Immunogenx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunogenx
Immunogenx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Immunogenx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunogenx
Complete news archive for Immunogenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunogenx
Immunogenx was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Immunogenx is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
As of Dec 31, 2022, the latest employee count at Immunogenx is 6.
Immunogenx develops solutions for the treatment and management of celiac disease. Its lead therapeutic candidate is a mixture of two gluten-specific recombinant proteases that helps in the degradation of gluten proteins in order to ameliorate the symptoms of celiac disease, when it was taken in conjunction with a gluten-free diet. It is currently in phase II clinical trials. Its lead diagnostic candidate CypCel is a metabolic assay. The patient is given a dose of the widely-used statin drug simvastatin, and the subsequent serum level of simvastatin is measured as a marker for the health of intestinal epithelium.
Immunogenx's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Immunogenx offers Therapeutic Solution.
Immunogenx has made 1 acquisition, including Alvine Pharma.
Immunogenx has 1 investor. Key investors include HHS.